托法替布在类风湿关节炎治疗中的临床研究进展
Advances in Clinical Study of Tofacitinib in the Treatment of Rheumatoid Arthritis
DOI: 10.12677/ACM.2021.1111736, PDF,  被引量    科研立项经费支持
作者: 姚 婷, 何 欣：川北医学院附属老年医学科，四川 南充；青玉凤：川北医学院附属风湿免疫科，四川 南充；四川大学华西医院精准医学研究中心，四川 成都
关键词: 类风湿关节炎；托法替布；JAK抑制剂；Rheumatoid Arthritis； Tofacitinib； JAK Inhibitor
摘要: 类风湿关节炎(RA)是一种以持续性滑膜炎、侵蚀性关节炎为特征的自身免疫病。近年来，研究发现JAK/STAT信号转导通路在RA发病中发挥着重要作用，成为了RA治疗的新靶点。新型口服药物托法替布(tofacitinib)能够选择性抑制JAK3信号转导通路，抑制RA患者滑膜成纤维细胞增殖及损伤软骨组织的进一步破坏，其对治疗RA的疗效及安全性已得到了充分研究和证实。本文就现阶段托法替布在类风湿关节炎治疗中的最新研究进展作一综述。
Abstract: Rheumatoid arthritis (RA) is an autoimmune disease characterized by persistent synovitis and erosive arthritis. In recent years, studies have found that JAK/STAT signal transduction pathway plays an important role in the pathogenesis of RA and has become a new target for RA therapy. Tofacitinib, a new oral drug, can selectively inhibit JAK3 signal transduction pathway and inhibit the proliferation of synovial fibroblasts and further damage of injured cartilage tissue in patients with RA. Its efficacy and safety in the treatment of RA have been fully studied and confirmed. This article reviews the latest research progress of tofacitinib in the treatment of rheumatoid arthritis.
文章引用：姚婷, 何欣, 青玉凤. 托法替布在类风湿关节炎治疗中的临床研究进展[J]. 临床医学进展, 2021, 11(11): 5009-5016. https://doi.org/10.12677/ACM.2021.1111736

参考文献

[1] 中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018, 57(4): 242-251.
[2] Zhang, X., Mu, R., Wang, X., Xu, C., Duan, T., An, Y., et al. (2015) The Impact of Rheumatoid Arthritis on Work Capacity in Chinese Patients: A Cross-Sectional Study. Rheumatology, 54, 1478-1487. [Google Scholar] [CrossRef] [PubMed]
[3] Zhu, H., Li, R., Da., Z., Bi, L., Li, X., Li, Y., et al. (2018) Remission Assessment of Rheumatoid Arthritis in Daily Practice in China: A Cross-Sectional Observational Study. Clinical Rheumatology, 37, 597-605. [Google Scholar] [CrossRef] [PubMed]
[4] Smolen, J.S., Aletaha, D., Bijlsma, J.W., et al. (2010) Treating Rheumatoid Arthritis to Target: Recommendations of an International Task Force. Annals of the Rheumatic Diseases, 69, 631-637. [Google Scholar] [CrossRef] [PubMed]
[5] Hodge, J.A., Kawabata, T.T., Krishnaswami, S., Clark, J.D., Telliez, J.B., Dowty, M.E., et al. (2016) The Mechanism of Action of Tofacitinib—An Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis. Clinical and Experimental Rheumatology, 34, 318-328.
[6] Villarino, A.V., Kanno, Y. and O’Shea, J.J. (2015) Mechanisms of Jak/STAT Signaling in Immunity and Disease. Journal of Immunology, 194, 21-27. [Google Scholar] [CrossRef] [PubMed]
[7] Tamai, M., Kawakami, A., Tanaka, F., Miyashita, T., Nakamura, H., Iwanaga, N., et al. (2006) Significant Inhibition of TRAIL-Mediated Fibroblast-Like Synovial Cell Apoptosis by IFN-Gamma through JAK/STAT Pathway by Translational Regulation. Journal of Laboratory and Clinical Medicine, 147, 182-190. [Google Scholar] [CrossRef] [PubMed]
[8] Carrara, G., Bortoluzzi, A., Sakellariou, G., Silvagni, E., Zanetti, A., Govoni, M., et al. (2019) Risk of Hospitalisation for Serious Bacterial Infections in Patients with Rheumatoid Arthritis Treated with Biologics. Analysis from the RECord linkage On Rheumatic Disease Study of the Italian Society for Rheumatology. Clinical and Experimental Rheumatology, 37, 60-66.
[9] Nakayamada, S., Kubo, S., Iwata, S. and Tanaka, Y. (2016) Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs, 30, 407-419. [Google Scholar] [CrossRef] [PubMed]
[10] Tanaka, Y., Takeuchi, T., Yamanaka, H., Nakamura, H., Toyoizumi, S. and Zwillich, S. (2015) Efficacy and Safety of Tofacitinib as Monotherapy in Japanese patients with Active Rheumatoid Arthritis: A 12-Week, Randomized, Phase 2 Study. Modern Rheumatology, 25, 514-521. [Google Scholar] [CrossRef] [PubMed]
[11] Fleischmann, R., Cutolo, M., Genovese, M.C., Lee, E.B., Kanik, K.S., Sadis, S., et al. (2012) Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) or Adalimumab Monotherapy versus Placebo in Patients with Active Rheumatoid Arthritis with an Inadequate response to Disease-Modifying Antirheumatic Drugs. Arthritis & Rheumatism, 64, 617-629. [Google Scholar] [CrossRef] [PubMed]
[12] Kremer, J.M., Cohen, S., Wilkinson, B.E., Connell, C.A., French, J.L., Gomez-Reino, J., et al. (2012) A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone. Arthritis & Rheumatism, 64, 970-981. [Google Scholar] [CrossRef] [PubMed]
[13] Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., et al. (2012) Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. New England Journal of Medicine, 367, 495-507. [Google Scholar] [CrossRef] 
[14] Burmester, G.R., Blanco, R., Charles-Schoeman, C.H., Wollenhaupt, J., Zerbini, C., Benda, B., et al. (2013) Tofacitinib (CP-690,550) in Combination with MTX in Patients with Active Rheumatoid Arthritis with an Inadequate Response to Tumour Necrosis Factor Inhibitors: A Randomized Phase III Trial. Lancet, 381, 451-460. [Google Scholar] [CrossRef] 
[15] Kremer, J., Li, Z.G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., et al. (2013) Tofacitinib in Combination with Non-Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Rheumatoid Arthritis: A Randomized Trial. Annals of Internal Medicine, 159, 253-261. [Google Scholar] [CrossRef] [PubMed]
[16] Van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., et al. (2013) Tofacitinib (CP-690,550) in Patients with Rheumatoid Arthritis Receiving MTX Twelve-Month Data from a Twenty-Four-Month Phase III Randomized Radiographic Study. Arthritis & Rheumatism, 65, 559-570. [Google Scholar] [CrossRef] [PubMed]
[17] Van Vollenhoven, R., Fleischmann, R., Cohen, S., Lee, E.B., García Meijide, J.A., Wagner, S., et al. (2012) Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. New England Journal of Medicine, 367, 508-519. [Google Scholar] [CrossRef] 
[18] Lee, E.B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J.D., Gruben, D., et al. (2014) Tofacitinib versus MTX in Rheumatoid Arthritis. New England Journal of Medicine, 370, 2377-2386. [Google Scholar] [CrossRef] 
[19] Strand, V., Kremer, J., Wallenstein, G., Kanik, K.S., Connell, C., Gruben, D., et al. (2015) Effects of Tofacitinib Monotherapy on Patient-Reported Outcomes in a Randomized Phase 3 Study of Patients with Active Rheumatoid Arthritis and Inadequate Responses to DMARDs. Arthritis Research & Therapy, 17, Article No. 307.
[20] Strand, V., Burmester, G.R., Zerbini, C.A., Mebus, C.A., Zwillich, S.H., Gruben, D., et al. (2015) Tofacitinib with Methotrexate in Third-Line Treatment of Patients with Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase III Trial. Arthritis Care & Research, 67, 475-483. [Google Scholar] [CrossRef] [PubMed]
[21] Strand, V., Kremer, J.M., Gruben, D., Krishnaswami, S., Zwillich, S.H. and Wallenstein, G.V. (2017) Tofacitinib in Combination with Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase III Randomized Controlled Trial. Arthritis Care & Research, 69, 592-598. [Google Scholar] [CrossRef] [PubMed]
[22] Strand, V., Lee, E.B., Fleischmann, R., Alten, R.E., Koncz, T., Zwillich, S.H., et al. (2016) Tofacitinib versus Methotrexate in Rheumatoid Arthritis: Patient-Reported Outcomes from the Randomised Phase III ORAL Start Trial. RMD Open, 2, Article ID: e000308. [Google Scholar] [CrossRef] [PubMed]
[23] Fleischmann, R., Mysler, E., Hall, S., Kivitz, A.J., Moots, R.J., Luo, Z., et al. (2017) Effificacy and Safety of Tofacitinib Monotherapy, Tofacitinib with MTX, and Adalimumab with MTX in Patients with Rheumatoid Arthritis (ORAL Strategy): A Phase IIIb/IV, Double-Blind, Head-to-Head, Randomized Controlled Trial. Lancet, 390, 457-468. [Google Scholar] [CrossRef] 
[24] Yamanaka, H., Tanaka, Y., Takeuchi, T., Sugiyama, N., Yuasa, H., Toyoizumi, S., et al. (2016) Tofacitinib, an Oral Janus Kinase Inhibitor, as Monotherapy or with Background Methotrexate, in Japanese Patients with Rheumatoid Arthritis: An Open-Label, Long-Term Extension Study. Arthritis Research & Therapy, 18, 34.
[25] Cohen, S.B., Tanaka, Y., Mariette, X., Curtis, J.R., Lee, E.B., Nash, P., et al. (2017) Long-Term Safety of Tofacitinib for the Treatment of Rheumatoid Arthritis up to 8.5 Years: Integrated Analysis of Data from the Global Clinical Trials. Annals of the Rheumatic Diseases, 76, 1253-1262. [Google Scholar] [CrossRef] [PubMed]
[26] Wollenhaupt, J., Lee, E.B., Curtis, J.R., Silverfield, J., Terry, K., Soma, K., et al. (2019) Safety and Efficacy of Tofacitinib for up to 9.5 Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study. Arthritis Research & Therapy, 21, Article No. 89. [Google Scholar] [CrossRef] [PubMed]
[27] Curtis, J.R., Xie, F., Yun, H., Bernatsky, S. and Winthrop, K.L. (2016) Real-World Comparative Risks of Herpes Virus Infections in Tofacitinib and Biologic-Treated Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 75, 1843-1847. [Google Scholar] [CrossRef] [PubMed]
[28] Winthrop, K.L., Melmed, G.Y., Vermeire, S., Long, M.D., Chan, G., Pedersen, R.D., et al. (2018) Herpes Zoster Infection in Patients with Ulcerative Colitis Receiving Tofacitinib. Inflammatory Bowel Diseases, 24, 2258-2265. [Google Scholar] [CrossRef] [PubMed]
[29] Moghoofei, M., Mostafaei, S., Ashraf-Ganjouei, A., Kavosi, H. and Mahmoudi, M. (2018) HBV Reactivation in Rheumatic Diseases Patients under Therapy: A Meta-Analysis. Microbial Pathogenesis, 114, 436-443. [Google Scholar] [CrossRef] [PubMed]
[30] Lau, C.S., Chia, F., Harrison, A., Hsieh, T.-Y., Jain, R., Jung, S.M., et al. (2015) APLAR Rheumatoid Arthritis Treatment Recommendations. International Journal of Rheumatic Diseases, 18, 685-713. [Google Scholar] [CrossRef] 
[31] Mori, S. and Fujiyama, S. (2015) Hepatitis B Virus Reactivation Associated with Antirheumatic Therapy: Risk and Prophylaxis Recommendations. World Journal of Gastroenterology, 21, 10274-10289. [Google Scholar] [CrossRef] [PubMed]
[32] van Vollenhoven, R., Lee, E.B., Strengholt, S., Mojcik, C., Valdez, H., Krishnaswami, S., et al. (2019) Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients with Rheumatoid Arthritis. Arthritis & Rheumatology, 71, 685-695. [Google Scholar] [CrossRef] [PubMed]
[33] Xie, F., Yun, H., Bernatsky, S. and Curtis, J.R. (2016) Brief Report: Risk of Gastrointestinal Perforation among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. Arthritis & Rheumatology, 68, 2612-2617. [Google Scholar] [CrossRef] [PubMed]
[34] Curtis, J.R., Lee, E.B., Kaplan, I.V., Kwok, K., Geier, J., Benda, B., et al. (2016) Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancies across the Rheumatoid Arthritis Clinical Development Programme. Annals of the Rheumatic Diseases, 75, 831-841. [Google Scholar] [CrossRef] [PubMed]
[35] Baecklund, E., Iliadou, A. and Askling, J. (2006) Association of Chronic Inflammation, Not Its Treatment, with Increased Lymphoma Risk in Rheumatoid Arthritis. Arthritis & Rheumatism, 54, 692-701. [Google Scholar] [CrossRef] [PubMed]
[36] Simon, T.A., Thompson, A., Gandhi, K.K., Hochberg, M.C. and Suissa, S. (2015) Incidence of Malignancy in Adult Patients with Rheumatoid Arthritis: A Meta-Analysis. Arthritis Research & Therapy, 17, Article No. 212. [Google Scholar] [CrossRef] [PubMed]
[37] Sivaraman, P. and Cohen, S.B. (2017) Malignancy and Janus Kinase Inhibition. Rheumatic Disease Clinics of North America, 43, 79-93. [Google Scholar] [CrossRef] [PubMed]
[38] Verden, A., Dimbil, M., Kyle, R., Overstreet, B. and Hoffman, K.B. (2018) Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors. Drug Safety, 41, 357-361. [Google Scholar] [CrossRef] [PubMed]
[39] Claxton, L., Jenks, M., Taylor, M., Wallenstein, G., Mendelsohn, A.M., Bourret, J.A., et al. (2016) An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. Journal of Managed Care & Specialty Pharmacy, 22, 1088-1102. [Google Scholar] [CrossRef] [PubMed]
[40] Claxton, L., Taylor, M., Soonasra, A., Bourret, J.A. and Gerber, R.A. (2018) An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis after Methotrexate or after 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. Journal of Managed Care & Specialty Pharmacy, 24, 1010-1017. [Google Scholar] [CrossRef] [PubMed]
[41] Tian, L., Xiong, X., Guo, Q., Chen, Y., Wang, L., Dong, P., et al. (2020) Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China. PharmacoEconomics, 38, 1345-1358. [Google Scholar] [CrossRef] [PubMed]

为你推荐